Table 4

Agreement and correlation of 10-year CVD risk algorithms across the entire study population, AWI-Gen baseline data

	WHO-CVD (lab)	WHO-CVD (office)	Globorisk (lab)	Globorisk (office)	Framingham (lab)
Framingham (office)
kappa (95% CI)	0.03 (0.03–0.04)**	0.04 (0.04–0.05)*	0.41 (0.39–0.43)**	0.52 (0.51–0.55)**	0.52 (0.51–0.54)**
Spearman’s correlation	0.28**	0.32**	0.64**	0.70**	0.70**
Framingham (lab)
kappa (95% CI)	0.08 (0.07–0.93)**	0.12 (0.11–0.13)**	0.55 (0.53–0.57)*	0.52 (0.50–0.54)**
Spearman’s correlation	0.32**	0.36**	0.66**	0.64**
Globorisk (office)
kappa (95% CI)	0.10 (0.09–0.12)**	0.12 (0.10–0.13)**	0.64 (0.62–0.67)*
Spearman’s correlation	0.32**	0.40**	0.74**
Globorisk (lab)
kappa (95% CI)	0.12 (0.11–0.14)**	0.18 (0.16–0.20)**
Spearman’s correlation	0.38**	0.42**
WHO-CVD (office)
kappa (95% CI)	0.58 (0.52–0.63)**
Spearman’s correlation	0.61**
		kappa agreement	<0.4 (poor)	0.41–0.60 (moderate)	0.61–0.80 (substantial)

*p<0.05; **p<0.0001.
AWI-GEN, Africa-Wits-INDEPTH partnership for Genomic studies; CVD, cardiovascular disease.